Update on Cancer Therapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 June 2026) | Viewed by 480
Editor
Special Issue Information
Dear Colleagues,
Cancer therapy continues to evolve, driven by advances in understanding tumor biology and the development of innovative treatments. Despite significant progress, formidable challenges such as therapy resistance, tumor heterogeneity, and metastatic recurrence remain major clinical hurdles. These limitations affect not only conventional chemotherapy but also modern approaches such as targeted agents and immunotherapies, often curtailing the durability of patient responses.
This Special Issue, titled “Update on Cancer Therapy”, aims to highlight cutting-edge research and comprehensive reviews on emerging therapeutic strategies. We welcome contributions that focus on novel molecular and immune targets, biomarker-driven treatment personalization, combination therapies, and innovative platforms such as cancer vaccines, CAR-T/NK cells, and nanomedicine. A key focus is on understanding and overcoming the mechanisms of primary and acquired resistance. By integrating multidisciplinary insights, this Special Issue seeks to foster the development of more effective and durable treatments, ultimately bridging transformative laboratory discoveries with clinical applications to improve patient outcomes.
Dr. Jian Ruan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- cancer immunotherapy
- targeted therapy
- ccancer vaccines
- therapeutic agents
- drug resistance mechanisms
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
